Immunohistochemical Detection of AR-V7 Protein in CRPC

Recent studies on in-situ detection of AR-V7 protein by IHC focused on
newly developed and validated antibodies ^{48 (link)–53 (link)}. Using
matched CSPC and CRPC tissue samples, nuclear AR-V7 protein detected by a rabbit
AR-V7 monoclonal antibody (EPR15656; Abcam, Burlingame, CA) was associated with
poor prognosis of CRPC patients after abiraterone or enzalutamide treatment
^{51 (link)}. Following detailed
characterization in clinical cohorts ^{13 (link),49 (link),54 (link)}, the EPIC CTC AR-V7 IHC test (Epic
Sciences, San Diego, CA) initially developed using the same anti-AR-V7 antibody
was recently implemented for clinical use (see companion review). In
tissue-based studies, the use of the RM7 (RevMab) antibody further established
CRPC-specific expression AR-V7 ^{48 (link),50 (link),55}. Interestingly, AR-V7 protein expression
was detected using this well-validated antibody in a subset of cells in small
cell prostate carcinoma and some salivary ductal carcinoma specimens from
untreated female patients ^{52 (link),56 (link)}. These recent studies on AR-V7
protein expression further supported that AR-V7 expression arises specifically
in a low androgen environment.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Lu C., Brown L., Antonarakis E.S., Armstrong A.J, & Luo J. (2020). Androgen Receptor Variant–Driven Prostate Cancer II: Advances in Laboratory Investigations. Prostate cancer and prostatic diseases, 23(3), 381-397.

Publication 2020

EPR15656

Abiraterone Androgen Antibodies Antibody Cells Companion Ductal carcinoma Enzalutamide Female Monoclonal antibody Nuclear protein Patients Prognosis Prostate carcinoma Protein Tissue

Corresponding Organization :

Other organizations : Johns Hopkins Medicine, Johns Hopkins University, Duke University

Top 5 similar protocols

Variable analysis

independent variables

Newly developed and validated antibodies used for in-situ detection of AR-V7 protein by IHC

dependent variables

Nuclear AR-V7 protein expression detected by a rabbit AR-V7 monoclonal antibody (EPR15656; Abcam, Burlingame, CA)
AR-V7 protein expression detected using the RM7 (RevMab) antibody

control variables

Matched CSPC and CRPC tissue samples

positive controls

The EPIC CTC AR-V7 IHC test (Epic Sciences, San Diego, CA) initially developed using the same anti-AR-V7 antibody

negative controls

Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!